Hasil Pencarian  ::  Simpan CSV :: Kembali

"Telah dilakukan penelitian samar ganda acak untuk menilai manfaat pemberian Asam Traneksamat pada 54 penderita hemoroid interna yang baru berdarah. Umur, kelamin, berat badan, tinggi badan, beratnya hemoroid serta lamanya onset perdarahan telah dibuat sebanding pada kedua kelompok. Efek hemostatik berupa berhentinya perdarahan didapatkan pada 100% (23/23) kelompok Asam Traneksamat pada hemoroid grade 2 sementara hanya 78.26% (18/23) pada kelompok plasebo. Setelah obsevasi 3 hari perdarahan berhenti lebih awal pada kelompok Asam Traneksamat dan secara statistik bermakna. Sejak hari ke empat kedua kelompok berbeda dalam hal perdarahan ulang. Pada kelompok plasebo rerata median perdarahan ulang setelah 36 hari, sementara kelompok Asam Traneksamat tidak pernah mencapai nilai median tertentu sampai akhir observasi. Kesimpulan: Asam Traneksamat efektif untuk menghentikan perdarahan pada hemoroid berdarah, dan mencegah perdarahan ulang.

---

Double blind randomized placebo controlled trial was conducted to evaluate the efficacy of Tranexamic acid in 54 patients with recent hemorrhoid bleeding. Age, gender, body weight, height, grade of hemorrhoid, time of onset of recent bleeding were comparable between two groups. Analysis of haemostatic effect or stop bleeding as an immediate outcome of this study revealed that in the grade 2 patients, 23/23 (100%) of tranexamic group and 18/23(78.26%) of placebo group the bleeding stop. After 3 days of observation, there was statistically significant different for the rate of stop bleeding as well as at the end of observation. Bleeding stop earlier in the Tranexamic group with median 4 days (3-5 days), compare to placebo, median 11(9.55-12.45). Analysis of recurrent bleeding as an outcome of this study revealed that in the placebo group 9/18(50%) of grade 2 patients and all grade 3 (100%)patients suffered from recurrent bleeding. Since the days 4, both group have significant different time for recurrent bleeding and at the end of observation, cumulative probability of free of bleeding between two groups significantly different. Median still stop bleeding in the placebo group was 36 days, and the tranexamic group never reaches the median until the end of observation. Conclusion: tranexamic acid was an effective drug to stop recent hemorrhoid bleeding and prevent further recurrent bleeding, significantly better than placebo."

"Pendahuluan: Sirosis hati merupakan penyebab mortalitas dan morbiditas global, terutama melalui komplikasi hipertensi porta yang menyebabkan perdarahan varises esofagus (VE). Pasien yang pernah mengalami perdarahan pertama memiliki tingkat kejadian perdarahan berulang yang tinggi dengan angka survival yang rendah. Meskipun endoskopi dapat memprediksi perdarahan berulang, pendekatan ini mahal dan bersifat invasif. Oleh karena itu, pemeriksaan non invasif lain dengan tingkat akurasi yang tinggi perlu dipelajari.Tujuan: Penelitian ini bertujuan untuk mengidentifikasi prediktor non-invasif perdarahan berulang VE (kekakuan hati, kekakuan limpa, skor Child Pugh, dan jumlah trombosit) pada pasien sirosis hati.Metode: Sebanyak 102 sampel pasien sirosis hati yang mengalami riwayat perdarahan VE. Variabel prediktor dalam memprediksi kejadian perdarahan berulang varises esofagus pada penelitian ini meliputi kekakuan hati, kekakuan limpa, skor Child Pugh, serta jumlah trombosit. Analisa multivariat dan uji skor dengan validasi internal untuk mendapatkan model performa terbaik sebagai prediktor perdarahan VE berulang.Hasil: Hasil menunjukkan bahwa kekakuan hati, kekakuan limpa, skor Child Pugh, dan trombositopenia signifikan sebagai prediktor perdarahan berulang VE. Dengan menggabungkan variabel ini, model prediksi dihasilkan dengan AUC 0,870. Diperoleh uji skor dengan validasi bahwa keempat variabel tersebut signifikan sebagai faktor yang berhubungan dengan perdarahan berulang varises esofagus. Kesimpulan: kombinasi kekakuan hati, kekakuan limpa, skor Child Pugh, dan jumlah trombosit memiliki performa baik dalam memprediksi risiko perdarahan varises esofagus berulang pada pasien sirosis hati.

---

Background: Liver cirrhosis is a global cause of mortality and morbidity, especially through complications of portal hypertension which causes esophageal variceal (VE) bleeding. Patients who have experienced a first bleed have a high rate of recurrent bleeding with a low survival rate. Although endoscopy can predict recurrent bleeding, this approach is expensive and invasive. Therefore, other non- invasive examinations with a high accuracy need to be researched.

Objective: This study aims to identify non-invasive predictors of recurrent VE bleeding (liver stiffness, spleen stiffness, Child Pugh score, and platelet count) in liver cirrhosis patients.

Methods: A total of 102 samples of liver cirrhosis patients who had a history of VE bleeding were included in this study. Predictor variables in predicting the incidence of recurrent esophageal variceal bleeding in this study include liver stiffness, spleen stiffness, Child Pugh score, and platelet count. Multivariate analysis and internal validity test were used to obtain the best performance model as a predictor of recurrent VE bleeding.

Results: The results showed that liver stiffness, spleen stiffness, Child Pugh score, and thrombocytopenia were significant as predictors of recurrent VE bleeding. By combining these variables, a prediction model was generated with an AUC of 0.870. Validity test of these four variables were significant as factors associated with recurrent esophageal variceal bleeding.

Conclusion: The combination of liver stiffness, spleen stiffness, Child Pugh score, and platelet count has good performance in predicting the risk of recurrent esophageal variceal bleeding in patients with liver cirrhosis."